These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15902461)

  • 1. Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
    Comella P; Massidda B; Palmeri S; Farris A; Lucia LD; Natale D; Maiorino L; Tafuto S; Cataldis GD; Casaretti R
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):481-6. PubMed ID: 15902461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
    Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.
    Comella P; Gambardella A; Farris A; Maiorino L; Natale D; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S;
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):133-9. PubMed ID: 15661564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
    Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
    Sehgal R; Lembersky BC; Rajasenan KK; Crandall TL; Balaban EP; Pinkerton RA; Kane P; Schmotzer A; Zeh H; Potter DM; Ramanathan RK
    Clin Colorectal Cancer; 2011 Jun; 10(2):117-20. PubMed ID: 21859564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
    Comella P; Massidda B; Filippelli G; Farris A; Natale D; Barberis G; Maiorino L; Palmeri S; Cannone M; Condemi G;
    J Cancer Res Clin Oncol; 2009 Feb; 135(2):217-26. PubMed ID: 18719941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical use of capecitabine plus oxaliplatin (CAPEOX) with bevacizumab for patients with metastatic colorectal cancer that cannot expect conversion therapy.
    Yokomizo H; Yoshimatsu K; Otani T; Osawa G; Nakayama M; Matsumoto A; Yano Y; Okayama S; Naritaka Y
    Hepatogastroenterology; 2013; 60(128):1911-5. PubMed ID: 24719926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
    Petrioli R; Bargagli G; Lazzi S; Pascucci A; Francini E; Bellan C; Conca R; Martellucci I; Fiaschi AI; Lorenzi B; Francini G;
    Anticancer Drugs; 2010 Mar; 21(3):313-9. PubMed ID: 20016369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
    Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
    J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
    Shields AF; Zalupski MM; Marshall JL; Meropol NJ
    Cancer; 2004 Feb; 100(3):531-7. PubMed ID: 14745869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
    Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
    J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
    Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 Sep; 33(9):4029-32. PubMed ID: 24023346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.
    Park YH; Lee JL; Ryoo BY; Ryu MH; Yang SH; Kim BS; Shin DB; Chang HM; Kim TW; Yuh YJ; Kang YK
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):623-9. PubMed ID: 17522863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
    Benavides M; Pericay C; Valladares-Ayerbes M; Gil-Calle S; Massutí B; Aparicio J; Dueñas R; González-Flores E; Carrato A; Marcuello E; Gómez A; Cabrera E; Queralt B; Gómez MJ; Guasch I; Etxeberría A; Alfaro J; Campos JM; Reina JJ; Aranda E
    Clin Colorectal Cancer; 2012 Sep; 11(3):200-6. PubMed ID: 22421001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
    Díaz-Rubio E; Tabernero J; Gómez-España A; Massutí B; Sastre J; Chaves M; Abad A; Carrato A; Queralt B; Reina JJ; Maurel J; González-Flores E; Aparicio J; Rivera F; Losa F; Aranda E;
    J Clin Oncol; 2007 Sep; 25(27):4224-30. PubMed ID: 17548839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
    Sastre J; Aranda E; Massutí B; Tabernero J; Chaves M; Abad A; Carrato A; Reina JJ; Queralt B; Gómez-España A; González-Flores E; Rivera F; Losa F; García T; Sanchez-Rovira P; Maestu I; Díaz-Rubio E
    Crit Rev Oncol Hematol; 2009 May; 70(2):134-44. PubMed ID: 19111473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.